Top 3 Trends Impacting the Global Kaposi Sarcoma Market Through 2021: Technavio

Technavio has published a new report on the global kaposi sarcoma market from 2017-2021. (Graphic: Business Wire)

???pagination.previous??? ???pagination.next???

LONDON--()--Technavio’s latest market research report on the global kaposi sarcoma market provides an analysis on the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

Sapna Jha, a lead analyst from Technavio, specializing in research on oncology sector, says, “The global Kaposi sarcoma market is expected to benefit from rising AIDS/HIV incidence across the globe. The condition seems to be more serious in the African region as this region has the largest number of HIV-positive population. Highly active antiretroviral therapy, at present is the most opted therapy for the disease.”

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

The top three emerging market trends driving the global kaposi sarcoma market according to Technavio research analysts are:

  • Increasing consolidation in the cancer treatment market
  • Emphasis on combination therapy
  • Application of Kaposi sarcoma-specific treatment

Increasing consolidation in the cancer treatment market

Past several years have witnessed significant consolidation in the cancer treatment industry. Studies have shown that there is a rise in a number of oncology clinics that got acquired by hospitals. Also, there has been rising consolidation among the vendors in the cancer treatment market. This trend is expected to further increase during the forecasted period.

For instance, in March 2015, Novartis completed its transaction with GlaxoSmithKline, including the acquisition of its oncology portfolio and some other businesses. The Kaposi sarcoma market is highly concentrated, and various initiatives in cancer treatment between the vendors, and between hospitals and clinics are expected to consolidate the market further.

Emphasis on combination therapy

Combination therapy is a therapy that uses more than one type of modality or medication. It is one of the major therapies included for the treatment of cancer and HIV/AIDS. The therapy may seem costlier than monotherapy but has many benefits associated with it. For instance, it reduces chances of drug resistance and exhibits lower failure rate, fewer side effects, and lower fatality ratios.

“Combination therapy is mostly used to prolong the life of the individuals and reduce the symptoms. Combination therapy is one of the most widely accepted therapies for Kaposi sarcoma,” says Sapna.

Combination antiretroviral therapy (ART) and the combination of chemotherapy and highly active antiretroviral therapy (HAART) are some of the combination therapies available for the treatment of Kaposi sarcoma.

Application of Kaposi sarcoma-specific treatment

The application of Kaposi sarcoma-specific treatments such as topical treatments, injections, or radiotherapy are the latest trends in the market. For instance, topical retinoid treatment involves applying the medicine directly on the lesion. Panretin, a retinoid drug related to vitamin A, is one such drug available for the treatment of Kaposi sarcoma skin lesion.

Radiation therapy is another suitable option available for the treatment of Kaposi sarcoma. These radiations are used for the reduction of symptoms of the disease such as swelling or pain. It is also being used for the treatment of skin lesions, especially for those that are present on visible parts of the body. Intralesional vinblastine injections have found application in the treatment of Kaposi sarcoma specifically in diabetic patients.

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like central nervous system, urology devices, and vaccines. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

Technavio’s latest market research report on the global kaposi sarcoma market provides an analysis of the most important trends expected to impact the market outlook from 2017-2021.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com